A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 May 2018
At a glance
- Drugs SHR 1316 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 21 May 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 21 May 2018 Planned primary completion date changed from 1 Feb 2018 to 30 Sep 2018.
- 21 May 2018 Status changed from recruiting to active, no longer recruiting.